New Thinking on “Smart” AI, QALY, Value Pricing, and Hematology Research
Artificial intelligence algorithms that can lead to better care and coverage. A fresh look at a familiar HEOR metric. An open, rigorous conversation about drug pricing. And a new partnership to advance hematology research in China. This issue of Health Care Bulletin explores these topics, which are transforming the landscape of health care consulting.
Click here to open the digitally enhanced format of the full issue or click on the links below to view individual articles.
In this issue:
In health care, newly developed artificial intelligence (AI) tools are opening the door to new diagnostic, research, and claims processing possibilities.
A discrete choice experiment methodology allows researchers to better assess the burden of disease on people with rare conditions.
Drug prices dominate the news in a way few other health care topics do.
There is a significant gap in the treatment for hematological diseases in China compared to other developed countries.
Also on analysisgroup.com
Analysis Group at Upcoming Conferences and Events
Analysis Group consultants will present recent work and participate on panels at major conferences in 2020. We also will host events to discuss current topics in the health care industry.
Business of Personalized Medicine (BPM) Summit
February 27, 2020
Analysis Group’s Law & Economics Symposium
June 8, 2020
Recent Health Care Videos
Our Health Care practice is distinguished by our capacity to provide expertise in matters related to HEOR, market access, epidemiology, and public policy, among other areas. In these recent videos, Analysis Group consultants address the challenges posed by rare disease research, the value of real-world evidence, and the importance of dossiers.